 |
 Video: What is a Stock Split?
|
|
|
| Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, Co. is studying several immuno-oncology drug candidates including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, Co. is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, Co.'s programs include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. to test the combination of NKTR-255. According to our Nektar Therapeutics stock split history records, Nektar Therapeutics has had 0 splits. | |
|
Nektar Therapeutics (NKTR) has 0 splits in our Nektar Therapeutics stock split history database.
Looking at the Nektar Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Nektar Therapeutics shares, starting with a $10,000 purchase of NKTR, presented on a split-history-adjusted basis factoring in the complete Nektar Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/22/2014 |
|
| End date: |
04/19/2024 |
|
| Start price/share: |
$12.26 |
|
| End price/share: |
$1.24 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-89.89% |
|
| Average Annual Total Return: |
-20.48% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1,011.03 |
|
| Years: |
10.00 |
|
|
|
|
|
